Focusing on drug versus disease mechanisms and on clinical subgrouping to advance personalised medicine in psychiatry

Acta Neuropsychiatrica

Volumn 26, Issue 6, 2014, Pages 327-333

  De Leon, Jose ^a,b  

^a Eastern State Hospital   (United States)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Alzheimer disease; individualised medicine; pharmacogenetics; pharmacogenomics; psychopharmacology

Indexed keywords

NEUROLEPTIC AGENT;

ALZHEIMER DISEASE; BRAIN; DEPRESSION; DRUG MECHANISM; HUMAN; MEDICAL DECISION MAKING; MENTAL DISEASE; PERSONALIZED MEDICINE; PRESCRIPTION; PSYCHIATRIST; PSYCHIATRY; REVIEW; SCHIZOPHRENIA; TREATMENT RESPONSE; CLASSIFICATION; GENETIC PREDISPOSITION; GENETICS; MENTAL DISORDERS; PHARMACOGENETICS; PSYCHOPHARMACOLOGY;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; MENTAL DISORDERS; PHARMACOGENETICS; PSYCHOPHARMACOLOGY;

EID: 84927574016     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1017/neu.2014.14     Document Type: Review

References (46)

1. OSBORN LA. Psychiatry and medicine: An introduction to personalized medicine. New York: McGraw Hill, 1952.
2. DE LEON J. Evidence-based medicine versus personalized medicine: are they enemies? J Clin Psychopharmacol 2012;32:153-164.
3. GARROD AE. Inborn errors of metabolism. London: Oxford University Press, 1909.
4. VOGEL F. Moderne probleme der Humangenetik. Ergeb Inn Med Kinderheild 1959;12:52-125.
5. KANIGEL R Apprentice to genius: the making of a scientific dynasty. New York: Macmillan Publishing Company, 1986.
6. BRODIE BB, COSMIDES GJ. Toxicology and the biomedical sciences. Science 1965;148:1547-1554.
7. MEYER UA. Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004;5: 669-676.
8. FODOR SP. Massively parallel genomics. Science 1997;277: 393-395.
9. Science. New research horizons. Science 1997;278:2039.
10. DE LEON J. The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res 2009;59:81-89.
11. HIEMKE C, BAUMANN P, BERGEMANN N et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011;44: 195-235.
12. CRETTOL S, DE LEON J, HIEMKE C, EAP C. Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine. Clin Pharmacol Ther 2014;95:254-257.
13. DE LEON J, SPINA E, DIAZ FJ. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Ther Drug Monitor 2013;35:30-47.
14. WAGNER JA. Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 2002;18:41-46.
15. DIENSTMANN R, RODON J, TABERNERO J. Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategies. Am Soc Clin Oncol Educ Book 2012;32:168-172.
16. WALDROP M. Complexity: the emerging science at the edge of order and chaos. New York: Touchstone Books, 1992.
17. BARABÁSI AL, GULBAHCE N, LOSCALZO J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011;12:56-68.
18. MCGORRY PD. Early clinical phenotypes, clinical staging, and strategic biomarker research: building blocks for personalized psychiatry. Biol Psychiatry 2013;74:394-395.
19. WEISSMAN MM, BROWN AS, TALATI A. Translational epidemiology in psychiatry: linking population to clinical and basic sciences. Arch Gen Psychiatry 2011;68:600-608.
20. WONG EH, FOX JC, NG MY et al. Toward personalized medicine in the neuropsychiatric field. Int Rev Neurobiol 2011;101:329-349.
21. HECKERS S. Future in psychopathology research. Schizophr Bull 2014;40(Suppl. 2):S147-S151.
22. OZOMARO U, WAHLESTEDT C, NEMEROFF CB. Personalized medicine in psychiatry: problems and promises. BMC Med 2013;11:132.
23. DE LEON J, ARMSTRONG SC, COZZA KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006;47: 75-85.
24. ARRANZ MJ, DE LEON J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007;12:707-747.
25. INSEL TR, SCOLNICK EM. Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol Psychiatry 2006;11:11-17.
26. KAPUR S, PHILLIPS AG, INSEL TR. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry 2012;17:1174-1179.
27. MCHUGH PR. Striving for coherence: psychiatry's efforts over classification. JAMA 2005;293:2526-2528.
28. LAIN ENTRALGO P. Historia de la medicina. Barcelona: Salvat, 1978.
29. DE LEON J. Is psychiatry scientific? A letter to a 21st century psychiatry resident. Psychiatry Investig 2013;10:205-217.
30. DE LEON J. One hundred years of limited impact of Jaspers' General Psychiatry in the US psychiatry. J Nerv Ment Dis 2014;202:79-87.
31. BERRIOS GE. Alzheimer's disease: a conceptual history. Int J Geriatr Psychiatry 1990;5:355-365.
32. DE LEON J. DSM-5 and research domain criteria: one hundred years after Jaspers's General Psychopathology. Am J Psychiatry 2014 May.
33. MORLEY JE. Alzheimer's disease: future treatments. J Am Med Dir Assoc 2011;12:1-7.
34. CRENSHAW DG, GOTTSCHALK WK, LUTZ MW et al. Using genetics to enable studies on the prevention of Alzheimer's disease. Clin Pharmacol Ther 2013;93:177-185.
35. BAN TA. Neuropsychopharmacology and the forgotten language of psychiatry. International Network for the History of Neuropsychopharmacology (INHN) E-Book, 2013. http://inhn.org/previews/neuropsychopharmacologyand- the-forgotten-language-of-psychiatry.html
36. ANDREASEN NC. DSM and the death of phenomenology in America: an example of unintended consequences. Schizophr Bull 2007;33:108-112.
37. BAN TA. Prolegomenon to the clinical prerequisite: psychopharmacology and the classification of mental disorders. Prog Neuropsychopharmacol Biol Psychiatry 1987;11:527-580.
38. BAN TA. Towards a clinical methodology for neuropsychopharmacological research. Neuropsychopharmacol Hung 2007;9:81-90.
39. HOENIG J. The concept of schizophrenia: Kraepelin - Bleuler - Schneider. Br J Psychiatry 1983;142:547-556.
40. LEONHARD K. Classification of endogenous psychoses, 5th edn. New York: Irvington Publisher, 1979.
41. ASTRUP C. Schizophrenia: conditional reflex studies. Springfield, IL: Thomas, 1962.
42. FISH F. The influence of the tranquillisers on the Leonhard schizophrenic syndromes. Encéphale 1964;53:245-249.
43. GUY W, BAN TA, WILSON WH. An international survey of tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:401-405.
44. BECKMANN H, FRITZE J, FRANZEK E. The influence of neuroleptics on specific syndromes and symptoms in schizophrenics with unfavourable long-term course. A 5-year follow-up study of 50 chronic schizophrenics. Neuropsychobiology 1992;26:50-58.
45. FIBIGER HC. Psychiatry, the pharmaceutical industry, and the road to better therapeutics. Schizophr Bull 2012;38:649-650.
46. STÖBER G, KOHLMANN B, IEKIERA M et al. Systematic mutation analysis of KIAA0767 and KIAA1646 in chromosome 22q-linked periodic catatonia. BMC Psychiatry 2005;5:36.